PURPOSE: To investigate variations of circulating serum levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and interleukin-10 (IL-10) during three-dimensional conformal radiation therapy (3D-CRT) in patients with non-small-cell lung cancer and correlate these variations with the occurrence of radiation pneumonitis. PATIENTS AND METHODS: Ninety-six patients receiving 3D-CRT for stage I to III disease were evaluated prospectively. Circulating cytokine levels were determined before, every 2 weeks during, and at the end of treatment. Radiation pneumonitis was evaluated prospectively between 6 and 8 weeks after 3D-CRT. The predictive value of clinical, dosimetric, and biologic (cytokine levels) factors was evaluated both in univariate and multivariate analyses. RESULTS: Forty patients (44%) experienced score 1 or more radiation pneumonitis. No association was found between baseline cytokine levels and the risk of radiation pneumonitis. In the whole population, mean levels of TNFalpha, IL-6, and IL-10 remained stable during radiotherapy. IL-6 levels were significantly higher (P = .047) during 3D-CRT in patients with radiation pneumonitis. In the multivariate analysis, covariations of IL-6 and IL-10 levels during the first 2 weeks of 3D-CRT were evidenced as independently predictive of radiation pneumonitis in this series (P = .011). CONCLUSION: Early variations of circulating IL-6 and IL-10 levels during 3D-CRT are significantly associated with the risk of radiation pneumonitis. Variations of circulating IL-6 and IL-10 levels during 3D-CRT may serve as independent predictive factors for this complication.
PURPOSE: To investigate variations of circulating serum levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and interleukin-10 (IL-10) during three-dimensional conformal radiation therapy (3D-CRT) in patients with non-small-cell lung cancer and correlate these variations with the occurrence of radiation pneumonitis. PATIENTS AND METHODS: Ninety-six patients receiving 3D-CRT for stage I to III disease were evaluated prospectively. Circulating cytokine levels were determined before, every 2 weeks during, and at the end of treatment. Radiation pneumonitis was evaluated prospectively between 6 and 8 weeks after 3D-CRT. The predictive value of clinical, dosimetric, and biologic (cytokine levels) factors was evaluated both in univariate and multivariate analyses. RESULTS: Forty patients (44%) experienced score 1 or more radiation pneumonitis. No association was found between baseline cytokine levels and the risk of radiation pneumonitis. In the whole population, mean levels of TNFalpha, IL-6, and IL-10 remained stable during radiotherapy. IL-6 levels were significantly higher (P = .047) during 3D-CRT in patients with radiation pneumonitis. In the multivariate analysis, covariations of IL-6 and IL-10 levels during the first 2 weeks of 3D-CRT were evidenced as independently predictive of radiation pneumonitis in this series (P = .011). CONCLUSION: Early variations of circulating IL-6 and IL-10 levels during 3D-CRT are significantly associated with the risk of radiation pneumonitis. Variations of circulating IL-6 and IL-10 levels during 3D-CRT may serve as independent predictive factors for this complication.
Authors: Jung Hun Oh; Jeffrey M Craft; Reid Townsend; Joseph O Deasy; Jeffrey D Bradley; Issam El Naqa Journal: J Proteome Res Date: 2011-02-16 Impact factor: 4.466
Authors: Ronny Kalash; Hebist Berhane; Jeremiah Au; Byung Han Rhieu; Michael W Epperly; Julie Goff; Tracy Dixon; Hong Wang; Xichen Zhang; Darcy Franicola; Ashwin Shinde; Joel S Greenberger Journal: In Vivo Date: 2014 Mar-Apr Impact factor: 2.155
Authors: Robert M Tighe; Karissa Heck; Erik Soderblom; Shutang Zhou; Anastasiya Birukova; Kenneth Young; Douglas Rouse; Jessica Vidas; Miglena K Komforti; Christopher B Toomey; Frank Cuttitta; Mary E Sunday Journal: Am J Pathol Date: 2019-03-18 Impact factor: 4.307
Authors: Peter G Hawkins; Philip S Boonstra; Stephen T Hobson; Jason W D Hearn; James A Hayman; Randall K Ten Haken; Martha M Matuszak; Paul Stanton; Gregory P Kalemkerian; Nithya Ramnath; Theodore S Lawrence; Matthew J Schipper; Feng-Ming Spring Kong; Shruti Jolly Journal: Radiother Oncol Date: 2017-09-23 Impact factor: 6.280
Authors: Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer Journal: Cancer Res Date: 2017-12-07 Impact factor: 12.701